BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of Neuroblastoma
Benzinga Newsdesk 2 months ago
FDANews
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1149926